Accessibility of Needle and Syringe Programs and Injecting and Sharing Risk Behaviors in High Hepatitis C Virus Prevalence Settings

References

• Abdul-Quader, A. S., Feelemyer, J., Modi, S., Stein, E. S., Briceno, A., Semaan, S., … Des Jarlais, D. C. (2013). Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: A systematic review. AIDS and Behavior, 17(9), 2878–2892. doi:10.1007/s10461-013-0593-y
   PubMed Web of Science ®Google Scholar
• Aceijas, C., Hickman, M., Donoghoe, M. C., Burrows, D., & Stuikyte, R. (2007). Access and coverage of needle and syringe programmes (NSP) in Central and Eastern Europe and Central Asia. Addiction, 102(8), 1244–1250. doi:10.1111/j.1360-0443.2007.01848.x
   PubMed Web of Science ®Google Scholar
• Alam-Mehrjerdi, Z. (2013). Norjizak injection: A critical risk for transmitting blood-borne infectious diseases. Hepatitis Monthly, 13(4), e8272. doi:10.5812/hepatmon.8272
   PubMed Web of Science ®Google Scholar
• Alam-Mehrjerdi, Z., Abdollahi, M., Higgs, P., & Dolan, K. (2015). Drug use treatment and harm reduction programs in Iran: A unique model of health in the most populated Persian Gulf country. Asian Journal of Psychiatry, 16, 78–83. doi:10.1016/j.ajp.2015.06.002
   PubMed Web of Science ®Google Scholar
• Allen, S. T., Ruiz, M. S., Jones, J., & Turner, M. M. (2016). Legal space for syringe exchange programs in hot spots of injection drug use-related crime. Harm Reduction Journal, 13, 16. doi:10.1186/s12954-016-0104-3
   PubMed Web of Science ®Google Scholar
• Allen, S., Ruiz, M., & O'Rourke, A. (2015). How far will they go? Assessing the travel distance of current and former drug users to access harm reduction services. Harm Reduction Journal, 12, 3. doi:10.1186/s12954-015-0043-4
   PubMed Web of Science ®Google Scholar
• Bastani, P., Marshall, B. D. L., Rahimi-Movaghar, A., & Noroozi, A. (2019). The risk environments of people who use drugs accessing two harm reduction centers in Tehran, Iran: A qualitative study. The International Journal of Drug Policy, 63, 90–96. doi:10.1016/j.drugpo.2018.11.013
   PubMed Web of Science ®Google Scholar
• Bruggmann, P., & Grebely, J. (2015). Prevention, treatment and care of hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy, 26(1), S22–S26. doi:10.1016/j.drugpo.2014.08.014
   PubMedGoogle Scholar
• Carlberg-Racich, S. (2016). Harm reduction interventions in HIV care: A qualitative exploration of patient and provider perspectives. PeerJ, 4, e1932. doi:10.7717/peerj.1932
   PubMed Web of Science ®Google Scholar
• Castillo, C. H. M., Garrafa, V., Cunha, T., & Hellmann, F. (2017). Access to health care as a human right in international policy: Critical reflections and contemporary challenges. Ciência & Saúde Coletiva, 22(7), 2151–2160. doi:10.1590/1413-81232017227.04472017
   PubMed Web of Science ®Google Scholar
• Chan, H. L. Y., Chen, C. J., Omede, O., Al Qamish, J., Al Naamani, K., Bane, A., … Nde, H. (2017). The present and future disease burden of hepatitis C virus infections with today's treatment paradigm. Journal of Viral Hepatitis, 24(2), 25–43. doi:10.1111/jvh.12760
   PubMedGoogle Scholar
• Cooper, H. L. F., Bossak, B., Tempalski, B., Des Jarlais, D. C., & Friedman, S. R. (2009). Geographic approaches to quantifying the risk environment: Drug-related law enforcement and access to syringe exchange programmes. International Journal of Drug Policy, 20(3), 217–226. doi:10.1016/j.drugpo.2008.08.008
   PubMed Web of Science ®Google Scholar
• Cooper, H. L., Des Jarlais, D. C., Ross, Z., Tempalski, B., Bossak, B., & Friedman, S. R. (2011). Spatial access to syringe exchange programs and pharmacies selling over-the-counter syringes as predictors of drug injectors' use of sterile syringes. American Journal of Public Health, 101(6), 1118–1125. doi:10.2105/AJPH.2009.184580
   PubMed Web of Science ®Google Scholar
• Day, E., Broder, T., Bruneau, J., Cruse, S., Dickie, M., & Fish, S. (2019). Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs. The International Journal of Drug Policy, 8(66), 87–93. doi:10.1016/j.drugpo.2019.01.012
   Google Scholar
• Deryabina, A., & El-Sadr, W. M. (2017). Uptake of needle and syringe program services in the Kyrgyz Republic: Key barriers and facilitators. Drug and Alcohol Dependence, 179, 180–186. doi:10.1016/j.drugalcdep.2017.07.002
   PubMed Web of Science ®Google Scholar
• Des Jarlais, D. C. (2013). Systematic review research on needle/syringe programs and opiate substitution programs in low- and middle-income countries. Journal of Food and Drug Analysis, 21(4), S59–S61. doi:10.1016/j.jfda.2013.09.035
   PubMedGoogle Scholar
• Durojaye, E. (2018). Human rights and access to healthcare services for indigenous peoples in Africa. Global Public Health, 13(10), 1399–1408. doi:10.1080/17441692.2017.1377745
   PubMed Web of Science ®Google Scholar
• Eckhardt, B., Winkelstein, E. R., Shu, M. A., Carden, M. R., McKnight, C., Des Jarlais, D. C., … Edlin, B. R. (2017). Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: Implications for prevention. PLoS One, 12(5), e0177341. doi:10.1371/journal.pone.0177341
   PubMed Web of Science ®Google Scholar
• Ezard, N. (2001). Public health, human rights and the harm reduction paradigm: From risk reduction to vulnerability reduction. The International Journal on Drug Policy, 12(3), 207–219. doi:10.1016/S0955-3959(01)00093-7
   Google Scholar
• Fernandes, R. M., Cary, M., Duarte, G., Jesus, G., Alarcão, J., & Torre, C. (2017). Effectiveness of needle and syringe programmes in people who inject drugs - An overview of systematic reviews. BMC Public Health, 17(1), 309. doi:10.1186/s12889-017-4210-2
   PubMed Web of Science ®Google Scholar
• Galea, S., Ahern, J., & Vlahov, D. (2003). Contextual determinants of drug use risk behavior: A theoretic framework. Journal of Urban Health, 80(4), iii50–iii58. doi:10.1093/jurban/jtg082
   PubMed Web of Science ®Google Scholar
• Galea, S., Nandi, A., & Vlahov, D. (2004). The social epidemiology of substance use. Epidemiologic Reviews, 26(1), 36–52. doi:10.1093/epirev/mxh007
   PubMed Web of Science ®Google Scholar
• Habibi, Z., Sobhi-Gharamaleki, N., & Bermas, H. (2011). Effectiveness of harm reduction program on addicts’ attitudes. Procedia - Social and Behavioral Sciences, 30, 1545–1548. doi:10.1016/j.sbspro.2011.10.300
   Google Scholar
• Heckathorn, D. D. (1997). Respondent-driven sampling: A new approach to the study of hidden populations. Social Problem, 44(2), 174–199. doi:10.2307/3096941
   Web of Science ®Google Scholar
• Heckathorn, D. D. (2002). Respondent-driven sampling II: Deriving valid population estimates from chain-referral samples of hidden populations. Social Problem, 49(1), 11–34. doi:10.1525/sp.2002.49.1.11
   Web of Science ®Google Scholar
• Himmich, H., & Madani, N. (2016). The state of harm reduction in the Middle East and North Africa: A focus on Iran and Morocco. International Journal of Drug Policy, 31, 184–189. doi:10.1016/j.drugpo.2016.02.013
   PubMed Web of Science ®Google Scholar
• Iversen, J., Grebely, J., Topp, L., Wand, H., Dore, G., & Maher, L. (2014). Uptake of hepatitis C treatment among people who inject drugs attending needle and syringe programs in Australia, 1999–2011. Journal of Viral Hepatitis, 21(3), 198–207. doi:10.1111/jvh.12129
   PubMed Web of Science ®Google Scholar
• Koester, S., Glanz, J., & Baron, A. (2005). Drug Sharing among heroin networks: Implications for HIV and Hepatitis B and C prevention. AIDS and Behavior, 9(1), 27–39. doi:10.1007/s10461-005-1679-y
   PubMed Web of Science ®Google Scholar
• Koo, F. K., Chen, X., Chow, E. P., Jing, J., Zheng, J., & Zhao, J. (2015). Barriers and potential improvements for needle and syringe exchange programs (NSPs) in China: A qualitative study from perspectives of both health and public security sectors. PLoS One, 10(6), e0130654. doi:10.1371/journal.pone.0130654
   PubMed Web of Science ®Google Scholar
• Larney, S., Peacock, A., Leung, J., Colledge, S., Hickman, M., Vickerman, P., Grebely, J., … Degenhardt, L. (2017). Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: A systematic review. The Lancet Global Health, 5(12), e1208–e1220. doi:10.1016/S2214-109X(17)30373-X
   PubMed Web of Science ®Google Scholar
• Mahmud, S., Akbarzadeh, V., & Abu-Raddad, L. J. (2018). The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses. Scientific Reports, 8(1), 150. doi:10.1038/s41598-017-18296-9
   PubMedGoogle Scholar
• Malekinejad, M., Navadeh, S., Lotfizadeh, A., Rahimi-Movaghar, A., Amin-Esmaeili, M., & Noroozi, A. (2015). High hepatitis C virus prevalence among drug users in Iran: Systematic review and meta-analysis of epidemiological evidence (2001–2012). International Journal of Infectious Diseases, 40, 116–130. doi:10.1016/j.ijid.2015.09.022
   PubMed Web of Science ®Google Scholar
• Momtazi, S., Noroozi, A., & Rawson, R. A. (2015). An overview of Iran drug treatment and harm reduction programs. In N. el-Guebaly, G. Carrà, & M. Galanter (Eds.), Textbook of addiction treatment: International Perspectives (543–554). Milano: Springer.
   Google Scholar
• Mumtaz, G. R., Awad, S. F., Feizzadeh, A., Weiss, H. A., & Abu-Raddad, L. J. (2018). HIV incidence among people who inject drugs in the Middle East and North Africa: Mathematical modelling analysis. Journal of the International AIDS Society, 21(3), e25102. doi:10.1002/jia2.25102
   PubMed Web of Science ®Google Scholar
• Noroozi, M., Noroozi, A., Sharifi, H., Harouni, G. G., Marshall, B. D. L., Ghisvand, H., … Armoon, B. (2019). Needle and syringe programs and hiv-related risk behaviors among men who inject drugs: A multilevel analysis of two cities in iran. International Journal of Behavioral Medicine, 26(1), 50–58. doi:10.1007/s12529-018-9758-4
   PubMed Web of Science ®Google Scholar
• Nouroz, F., Shaheen, S., Mujtaba, G., & Noreen, S. (2015). An overview on hepatitis C virus genotypes and its control. The Egyptian Journal of Medical Human Genetics, 16(4), 291–298. doi:10.1016/j.ejmhg.2015.05.003
   Google Scholar
• Palmateer, N., Kimber, J., Hickman, M., Hutchinson, S., Rhodes, T., & Goldberg, D. (2010). Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users. A review of reviews. Addiction, 105(5), 844–859. doi:10.1111/j.1360-0443.2009.02888.x
   PubMed Web of Science ®Google Scholar
• Parker, J., Jackson, L., Dykeman, M., Gahagan, J., & Karabanow, J. (2012). Access to harm reduction services in Atlantic Canada: Implications for non-urban residents who inject drugs. Health Place, 18(2), 152–162. doi:10.1016/j.healthplace.2011.08.016
   PubMed Web of Science ®Google Scholar
• Pozzetto, B., Memmi, M., Garraud, O., Roblin, X., & Berthelot, P. (2014). Health care-associated hepatitis C virus infection. World Journal of Gastroenterology, 20(46), 17265–17278. doi:10.3748/wjg.v20.i46.17265
   PubMed Web of Science ®Google Scholar
• Rezaie, F., Farhadi, M. H., Farhoudian, A., Najafi, M., Bazrafshan, A., & Higgs, P. (2017). Access to needle and syringe programs and the relationship to equipment sharing among people who inject drugs in Kermanshah, Iran. Journal of Substance Use, 22(4), 397–402. doi:10.1080/14659891.2016.1227384
   Web of Science ®Google Scholar
• Rhodes, T. (2002). The ‘risk environment’: A framework for understanding and reducing drug-related harm. The International Journal of Drug Policy, 13(2), 85–94. doi:10.1016/S0955-3959(02)00007-5
   Google Scholar
• Rhodes, T. (2009). Risk environments and drug harms: A social science for harm reduction approach. The International Journal of Drug Policy, 20(3), 193–201. doi:10.1016/j.drugpo.2008.10.003
   PubMed Web of Science ®Google Scholar
• Rhodes, T., Singer, M., Bourgois, P., Friedman, S. R., & Strathdee, S. A. (2005). The social structural production of HIV risk among injecting drug users. Social Science & Medicine, 61(5), 1026–1044. doi:10.1016/j.socscimed.2004.12.024
   PubMed Web of Science ®Google Scholar
• Roshanfekr, P., Noori, R., Dejman, M., Fathi Geshnigani, Z., & Rafiey, H. (2015). Drug use and sex work among at-risk women: A qualitative study of initial factors. Iranian Journal of Psychiatry and Behavioral Sciences, 9(2), e953. doi:10.17795/ijpbs953
   PubMed Web of Science ®Google Scholar
• Singh, P. S. J., Azman, A., Samsurijan, M. S., Badaruddin, R. F. R., Vadevelu, K., Yahaya, M. H., A., & Latiff, A. R. (2016). Implementation dilemmas of the Needle Syringe Exchange Programme (NSEP): Between the law and prevention. Pacific Science Review B: Humanities and Social Sciences, 2(2), 53–57. doi:10.1016/j.psrb.2016.09.005
   Google Scholar
• Small, W., Rhodes, T., Wood, E., & Kerr, T. (2007). Public injection settings in Vancouver: Physical environment, social context and risk. International Journal of Drug Policy, 18(1), 27–36. doi:10.1016/j.drugpo.2006.11.019
   PubMed Web of Science ®Google Scholar
• Solomon, S. S., Mehta, S. H., Srikrishnan, A. K., Solomon, S., McFall, A. M., & Laeyendecker, O. (2015). Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: A cross-sectional study. The Lancet Infectious Diseases, 15(1), 36–45. doi:10.1016/S1473-3099(14)71045-X
   PubMed Web of Science ®Google Scholar
• Strike, C., & Miskovic, M. (2018). Scoping out the literature on mobile needle and syringe programs-review of service delivery and client characteristics, operation, utilization, referrals, and impact. Harm Reduction Journal, 15(1), 6. doi:10.1186/s12954-018-0212-3
   PubMedGoogle Scholar
• Taherkhani, R., & Farshadpour, F. (2015). Epidemiology of hepatitis C virus in Iran. World Journal of Gastroenterology, 21(38), 10790–10810. doi:10.3748/wjg.v21.i38.10790
   PubMed Web of Science ®Google Scholar
• United Nations. (1948). Universal Declaration of Human Rights. United Nations General Assembly Resolution 217 A (III). New York: United Nations.
   Google Scholar
• Vazirian, M., Nassirimanesh, B., Zamani, S., Ono-Kihara, M., Kihara, M., & Ravari, S. M. (2005). Needle and syringe sharing practices of injecting drug users participating in an outreach HIV prevention program in Tehran, Iran: A cross-sectional study. Harm Reduction Journal, 2(1), 19. doi:10.1186/1477-7517-2-19
   PubMedGoogle Scholar
• Vearrier, L. (2018). The value of harm reduction for injection drug use: A clinical and public health ethics analysis. Disease-a-Month, 65, 119–141. pii: S0011-5029(18)30161-5. doi:10.1016/j.disamonth.2018.12.002
   PubMed Web of Science ®Google Scholar
• Wolfe, D., Luhmann, N., Harris, M., Momenghalibaf, A., Albers, E., Byrne, J., & Swan, T. (2015). Human rights and access to hepatitis C treatment for people who inject drugs. International Journal of Drug Policy, 26(11), 1072–1080. doi:10.1016/j.drugpo.2015.05.007
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2000). World Health Organization Drug Injecting Study. Phase II operations manual. Retrieved from http://www.who.int/substance_abuse/activities/en/WHODrugInjectionStudyOperationsManul.pdf
   Google Scholar
• World Health Organization. (2012). WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. Geneva: World Health Organization.
   Google Scholar
• World Health Organization. (2014). Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva: World Health Organization.
   Google Scholar
• World Health Organization. (2017a). Global hepatitis report. Retrieved from http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en.pdf
   Google Scholar
• World Health Organization. (2017b). Human rights and health. Retrieved from http://www.who.int/news-room/fact-sheets/detail/human-rights-and-health
   Google Scholar
• Wright, N. M. J., Tompkins, C. N. E., & Jones, L. (2004). Exploring risk perception and behaviour of homeless injecting drug users diagnosed with hepatitis C. Health & Social Care in the Community, 13(1), 75–83. doi:10.1111/j.1365-2524.2005.00552.x
   Web of Science ®Google Scholar
• Zamani, S., Vazirian, M., Nassirimanesh, B., Razzaghi, E. M., Ono-Kihara, M., & Mortazavi Ravari, S. (2010). Needle and syringe sharing practices among injecting drug users in Tehran: A comparison of two neighborhoods, one with and one without a needle and syringe program. AIDS and Behavior, 14(4), 885–890. doi:10.1007/s10461-008-9404-2
   PubMed Web of Science ®Google Scholar
• Zhang, L., Chen, X., Zheng, J., Zhao, J., Jing, J., Zhang, J., … Wilson, D. P. (2013). Ability to access community-based needle-syringe programs and injecting behaviors among drug users: A cross-sectional study in Hunan Province, China. Harm Reduction Journal, 10, 8. doi:10.1186/1477-7517-10-8
   PubMed Web of Science ®Google Scholar